Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC05F01 in Chinese Patients with Advanced or Metastatic Solid Tumors
NCT06873542Phase 1Completed
- Sponsor
- HeraNova Lifesciences
- Start
- Jul 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DC05F01 in solid tumor, sponsored by HeraNova Lifesciences. Primary endpoint: Number of Participants With Adverse Events at 6 months. Started Jul 2022; status: completed.
02
Drugs
DC05F01
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06873542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06873542.